Financing ·
AbCellera Biologics Inc. priced an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75…
ABCLAbCellera Biologics Inc.
AbCellera Biologics Inc. priced an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants for up to 3,076,926 additional shares at $9.74999 each. The transaction generates approximately $200 million in gross proceeds and $187 million in net proceeds after underwriting discounts and expenses. Jefferies LLC and J.P. Morgan Securities LLC served as representatives for the underwriters, which also included Cantor Fitzgerald, UBS Investment Bank, and BMO Capital Markets. The offering closed on August 14, 2026, with a 60-day lock-up agreement in place for insiders. AbCellera intends to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including lead program ABCL635, as well as for working capital and general corporate purposes. The company operates in the biotechnology industry, focusing on discovering and developing antibody-based medicines.